2.5. Study Endpoints
myocardial damage, LV diastolic dysfunction, RV dysfunction, LV systolic dysfunction, LV dysfunction, myocardial injury
ADVERSE EFFECTS
The primary endpoint of this study was the incidence of LV dysfunction as measured by a relative decline in the GLS of >15% from the baseline value.Secondary endpoints of the trial:Incidence of myocardial damage as measured by elevated high-sensitivity cardiac Tn I.Incidence of myocardial injury according to elevated NT-proBNP levels.Incidence of LV diastolic dysfunction.Incidence of LV systolic dysfunction measured by EF and symptomatic HF.Incidence of RV dysfunction.Changes in myocardial work parameters by the 2D strain–pressure loop.Incidence of adverse effects of ivabradine.The protocol scheme is depicted in 